Recent Reports


2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 38 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Analyst Interview Excerpt
OPPORTUNITIES IN BIOTECHNOLOGY: RENI BENJAMIN - RODMAN & RENSHAW


Full article published: 08/25/2003


For Subscribers

Get this article online now!

Order just this article
TWST: Reni, you're putting on a biotech conference. Could you tell us about that?
Dr. Benjamin: By way of background, Rodman & Renshaw is a full-service investment bank with a focus on small to mid-cap biotechnology and technology companies. We are committed to the long-term development of emerging companies through value-added equity research, institutional sales and trading, strategic advice, and capital raising. Our equity research, sales and trading efforts cater only to institutional clients looking to invest in undervalued, under-covered companies with outstanding technologies. Currently, the biotechnology team consists of seven PhDs of which four are senior analysts including myself, Elemer Piros, David Wood and Navdeep Jaikaria. Combined, we cover a wide range of therapeutic categories including oncology, cardiology, infectious disease, inflammation and autoimmune diseases. Companies currently under coverage by the biotech team at Rodman include Aksys (AKSY), Alteon (ALT), Ariad Pharmaceutical (ARIA), Applied Molecular Evolution (AMEV), AVI BioPharma (AVII), Cepheid (CPHD), CollaGenex Pharmaceuticals (CGPI), Cypress Bioscience (CYPB), Dyax (DYAX), Encysive Pharmaceuticals (ENCY), Genelabs Technologies (GNLB), Genta (GNTA), Geron (GERN), InKine Pharmaceuticals (INKP), Isis Pharmaceuticals (ISIS), Repligen (RGEN), Rita Medical Systems (RITA), SuperGen (SUPG), Tanox (TNOX) and United Therapeutics (UTHR). As part of Rodman and Renshaw's continued growth and development, the company acquired all the rights to the Annual Techvest Healthcare Conference. The conference, to be held in Boston from October 21-23, 2003, will host over 150 public and private companies, as well as a large number of institutional and venture capital investors.

TWST: What are you going to do with it?
Dr. Benjamin: In addition to panel discussions with independent experts helping to sift through complex issues surrounding biotechnology and thought provoking and vibrant keynote speakers, we will showcase upcoming growth companies that we believe comprise the next generation of biotechnology companies. We already have over 150 public and private companies presenting to a large audience of institutional investors.

 

Tickers included in this excerpt: AKSY, ALT, AMEV, ARIA, ASCO, AVII, AZN, BGEN, BMRN, CGPI, CPHD, CYPB, DNA, DYAX, ENCY, GENZ, GERN, GNLB, GNTA, INKP, ISIS, MEDI, MLNM, NVS, RGEN, RITA, SUPG, TNOX, UTHR

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.